Form 4: Strata Critical Medical Insider Trades Class A Stock

Amir Cohen, Chief Accounting Officer of Strata Critical Medical, Inc., reported transactions involving Class A common stock, executed under a Rule 10b5-1 trading plan.

Summary

• Amir Cohen, Chief Accounting Officer at Strata Critical Medical, Inc., engaged in transactions involving the company's Class A common stock.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan, adopted on December 10, 2025.
• On May 21, 2026, 10,300 shares were acquired at a price of $5.79 per share.
• On May 22, 2026, an additional 40,575 shares were acquired at a weighted average price of $5.91, with individual sales ranging from $5.81 to $6.02.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves insider transactions, the execution under a Rule 10b5-1 plan suggests a structured approach rather than a strong signal of positive or negative sentiment.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less opportunistic trading activity.
• The reporting person acquired shares, which could be interpreted as a positive signal of confidence in the company's future.

Negatives

• The filing details the disposal of securities, which can sometimes be perceived negatively by the market, although in this case, it's part of a pre-arranged plan.
• The weighted average price for the May 22nd transaction indicates a range of sale prices, suggesting multiple trades occurred.

Risks

• The primary risk associated with insider trading, even under a Rule 10b5-1 plan, is the potential for market perception to negatively impact share price if the trades are interpreted as a lack of confidence, despite the plan's intent.
• The specific details of the Rule 10b5-1 plan are not disclosed, leaving room for speculation about the underlying motivations for the trades.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan is a common strategy for executives to manage their stock holdings while adhering to insider trading regulations, aiming to mitigate concerns about opportunistic trading.

Stakeholder Impact

• Shareholders: The transactions, being pre-planned, are unlikely to cause significant immediate impact, but ongoing monitoring of insider activity is standard practice.
• Management: The use of a Rule 10b5-1 plan demonstrates adherence to corporate governance best practices regarding insider trading.

Next Steps

• The reporting person may be required to provide further details on specific sale prices upon request from the SEC, security holders, or the Issuer.

Key Dates

Keywords

SEC Form 4, Insider Trading, Strata Critical Medical, SRTA, Class A Common Stock, Rule 10b5-1, Beneficial Ownership, Securities Transaction